title: Increased proportion of HLA-class-I-specific natural killer cell receptors (CD94) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation.
abstract: In the present study, we investigated the inhibitory natural killer cell receptor (NKR) expression of CD94/NKG2A on PBMC after allogeneic bone marrow transplantation (BMT). The proportion of CD94 expression on PBMC was higher in patients without chronic graft-versus-host disease (cGVHD) and also in cGVHD patients with good response to conventional immunosuppressive therapy than in cGVHD patients with poor response. Also, the proportions of CD94+/CD3+ cells and CD94+/CD8+ cells were higher in cGVHD patients showing good response. In addition, the proportion of NKG2A-expressing cells was higher in patients without cGVHD than in patients with cGVHD. Therefore, chronic allostimulation after allo-BMT may augment the proportion of CD94/NKG2A-positive cells, and these cells may play some role in the regulation of alloresponse in some patients.
authors.affiliation: Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Tutumi
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: A
authors.initials: A
authors.lastname: Mori
authors.forename: K
authors.initials: K
authors.lastname: Kahata
authors.forename: N
authors.initials: N
authors.lastname: Toyoshima
authors.forename: S
authors.initials: S
authors.lastname: Ohta
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Hashino
authors.forename: M
authors.initials: M
authors.lastname: Asaka
authors.forename: M
authors.initials: M
authors.lastname: Imamura
mesh_terms: D015703:Antigens, CD / Q000378:metabolism*; D016026:Bone Marrow Transplantation / Q000276:immunology; D017252:CD3 Complex; D018414:CD8-Positive T-Lymphocytes; D016022:Case-Control Studies; D006086:Graft vs Host Disease / Q000097:blood / Q000276:immunology; D019337:Hematologic Neoplasms / Q000097:blood / Q000150:complications / Q000628:therapy; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology / Q000378:metabolism; D037181:Lectins, C-Type; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000378:metabolism*; D055654:NK Cell Lectin-Like Receptor Subfamily C; D051920:NK Cell Lectin-Like Receptor Subfamily D; D011971:Receptors, Immunologic / Q000378:metabolism; D055607:Receptors, Natural Killer Cell; D013601:T-Lymphocytes; D014184:Transplantation, Homologous / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD; D017252:CD3 Complex; C527054:KLRC1 protein, human; C497869:KLRD1 protein, human; D037181:Lectins, C-Type; D008562:Membrane Glycoproteins; D055654:NK Cell Lectin-Like Receptor Subfamily C; D051920:NK Cell Lectin-Like Receptor Subfamily D; D011971:Receptors, Immunologic; D055607:Receptors, Natural Killer Cell